Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Company has allotted 3,85,10,000 warrants to Shanghvi Finance at an issue price of Rs 155.80/- per warrant on preferential basis, out of which the Company has received an amount of Rs 149.99 crore which is equivalent to 25% of the warrant issue price. Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of face value of Re 1/- of the Company in accordance with the provisions of SEBI ICDR Regulations.

Net profit of Sun Pharma Advanced Research Company reported to Rs 1761.34 crore in the quarter ended March 2026 as against net loss of Rs 59.77 crore during the previous quarter ended March 2025. Sales declined 51.45% to Rs 13.20 crore in the quarter ended March 2026 as against Rs 27.19 crore during the previous quarter ended March 2025. For the full year,net profit reported to Rs 1553.20 crore in the year ended March 2026 as against net loss of Rs 342.51 crore during the previous year ended March 2025. Sales declined 45.45% to Rs 39.15 crore in the year ended March 2026 as against Rs 71.77 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales13.2027.19 -51 39.1571.77 -45 OPM %13433.33-195.59 -4083.68-450.24 - PBDT1763.36-57.72 LP 1575.58-330.39 LP PBT1760.96-60.67 LP 1565.37-342.78 LP NP1761.34-59.77 LP 1553.20-342.51 LP Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 18 May 2026.

Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million upon the closing of the transaction. PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby' indicated for the treatment of neonatal seizures. 'The sale of the PRV will enable us to accelerate the development of our pipeline assets and strengthen our external innovation strategy, which has already delivered multiple additions to our portfolio,' said Anil Raghavan, CEO of SPARC. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.

Sun Pharma Advanced Research Company announced that Dr. Shravanti Bhowmik, Head of Operations Management, and a member of Senior Management Team of the Company has resigned from her position in the Company with effect from the close of business hours on 31 March 2026.

Net Loss of Sun Pharma Advanced Research Company reported to Rs 80.42 crore in the quarter ended December 2025 as against net loss of Rs 79.51 crore during the previous quarter ended December 2024. Sales declined 43.33% to Rs 8.45 crore in the quarter ended December 2025 as against Rs 14.91 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales8.4514.91 -43 OPM %-670.30-494.23 - PBDT-65.42-76.30 14 PBT-67.99-79.44 14 NP-80.42-79.51 -1 Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Sun Pharma Advanced Research Company announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 February 2026.Powered by Capital Market - Live

The board will evaluate a proposal to raise funds through a preferential issue, including convertible warrants, to an identified member of the promoter group, subject to receipt of all requisite approvals, consents and permissions, including from the company's shareholders as well as the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE). Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. The company had reported a consolidated net loss of Rs 75.85 crore in the quarter ended September 2025 as against net loss of Rs 107.33 crore during the previous quarter ended September 2024. Sales declined 38.88% to Rs 7.86 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 14 January 2026.Powered by Capital Market - Live